CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Curanex Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$4.92+0.30 (+6.49%)
Close on Oct 19, 2026
- Market cap
- $139.55M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Curanex Pharmaceuticals has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Curanex Pharmaceuticals filed with the SEC
Curanex Reports First Quarter 2026 Business Progress
Regulation FD disclosure · EX-99.1 to Form 8-K
Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Inc. Announces Exercise of the
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K